Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
NCT ID: NCT00002446
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
1998-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Posaconazole
Fluconazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are at least 18 years old.
* Are HIV-positive.
* Have thrush (oropharyngeal candidiasis).
* Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).
* Are able to take study medication and return for clinic visits during the study.
* Are expected to live for at least 2 months.
Exclusion Criteria
* Have received protease inhibitors for the first time within 30 days prior to study entry.
* Have received certain medications.
* Have certain other types of fungal infections.
* Have certain types of cancer.
* Have received SCH 56592 within 3 months prior to study entry.
* Are pregnant or breast-feeding.
* Cannot take medications by mouth.
* Are allergic to azole drugs.
* Have certain medical conditions.
* Have been in this study before.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schering-Plough
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Bay AIDS Ctr
Berkeley, California, United States
ViRx Inc
San Francisco, California, United States
Kaiser Foundation Hospital
San Francisco, California, United States
Infectious Disease and AIDS Clinic
Denver, Colorado, United States
Dupont Circle Physicians Group
Washington D.C., District of Columbia, United States
Boulevard Comprehensive Care Ctr
Jacksonville, Florida, United States
Miami Veterans Administration Med Ctr
Miami, Florida, United States
TRIAD Health Practice
Chicago, Illinois, United States
Community Hosp Indianapolis
Indianapolis, Indiana, United States
Wayne State Univ / Harper Hosp
Detroit, Michigan, United States
UMDNJ - New Jersey Med School / Cooper Hosp
Camden, New Jersey, United States
Jersey City Med Ctr
Jersey City, New Jersey, United States
SUNY / Health Science Ctr at Brooklyn
Brooklyn, New York, United States
Univ of Pennsylvania School of Dental Medicine
Philadelphia, Pennsylvania, United States
Med Univ of South Carolina
Charleston, South Carolina, United States
Amelia Ct Clinic
Dallas, Texas, United States
Univ of Texas Health Sciences Ctr
San Antonio, Texas, United States
Queen Elizabeth Hosp Respiratory Unit
Saint Michael, , Barbados
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C97-331
Identifier Type: -
Identifier Source: secondary_id
I97-331
Identifier Type: -
Identifier Source: secondary_id
305A
Identifier Type: -
Identifier Source: org_study_id